 |
|
|
| |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in a Test-and-Treat Model of Care for HIV-1 Infection:
Interim Analysis of the DIAMOND Study
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, 23-27 July 2018, Amsterdam, the Netherlands
Gregory D. Huhn,1,* Gordon Crofoot,2 Moti Ramgopal,3 Joseph Gathe Jr,4 Robert Bolan,5 Ceyhun Bicer,6 Richard Bruce Simonson,7 Richard E. Nettles,7 Keith Dunn7
1The Ruth M. Rothstein CORE Center, Chicago, IL, USA; 2Crofoot Research Center, Houston, TX, USA; 3Midway Immunology and Research Center, Fort Pierce, FL, USA; 4Therapeutic Concepts, Houston, TX, USA; 5Los Angeles LGBT Center, Los Angeles, CA, USA; 6BICER Consulting & Research, Antwerp, Belgium; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
